SARS-CoV-2 Clinician Tools


On average, COVID-19 cases may be 10x higher than what is currently being recordEd1

We must identify new, recent and past infections to understand true spread and contain outbreaks.

Serology testing can help.

 

 


 
                                                                                                                         
Resources & Tools



clinician-serology-testing-infographic_220x100.png
Serology testing infographic 

A printable document that explains the value of serology tests and the need to more accurately identify infections.

Download the Infographic
clinician-tool-slide-rule_220x100.png
Interactive COVID-19 test tool

Understand how COVID-19 tests can be used to understand a patient's status throughout the course of infection and recovery.

Use the interactive test tool

clinician-serology-whitepaper_220x100.jpg
Clinical Assessment White Paper

A consolidation of literature that discusses the value of combining serology with RNA and Antigen tests in a clinical environment.

Read the clinician white paper 
clinician-serology-webinars_220x100.jpg
covid-19 clinician webinars 

Webinars and conversations with clinicians about managing patient care during the pandemic.

 Watch clinician webinars

 

 

 
 
 

There are Challenges Diagnosing Both Acute Symptomatic and Asymptomatic COVID-19 Infections―And This Will Only Grow More Challenging During Flu and Cold Season  

SARS-CoV-2_icons-patient.png

 

 

We need to identify all infected patients to better understand impacts on patient wellness moving forward

clinician-organ-injury-icons.png


What can be done?
Serology tests can... 

 
 
SARS-CoV-2_icons-1a-02.png

Allow identification of recent infection and evaluation of disease course 
 
SARS-CoV-2_icons-2a-02.png

Differentiate current, recent and previous infections
 
SARS-CoV-2_icons-3a-02.png

Identify recent or prior infection for patients with no known exposure or symptoms

Serology Testing is Essential to manage the pandemic and Patient care

Serology testing is important for health management of individual patients and the community at large.

Download the PDF Infographic  

 

Resources to help you manage Patient Care

Abbott is committed to support communities worldwide with resources and technologies to fight the evolving threat of COVID-19. As you work to continue to respond to the pandemic and provide patient care, we hope you find these resources helpful.


Download the PDF Version of the Tool

 

covid-19_whitepaper_Page_1.jpg


Clinical Assessment of COVID-19

A consolidation of literature that discusses the value of combining serology with RNA and Antigen COVID-19 tests in a clinical environment. 

The paper also shares common patient presentation scenarios that clinicians are being faced with and ideas of what types of testing they may consider to help stem the spread of COVID-19 and manage patient care.

Read the clinician white paper
Back to Top

Clinician Webinars


Explore 


Infectious Disease Icon.png

Infectious Disease Assays 

Our extensive assay menu helps physicians make timely, informed decisions throughout the continuum of care. 

Explore Infectious Disease  

portal_image_300x200.jpg

SARS-CoV-2 Serology

Explore our automated lab-based tests that detects the human-antibody response to the novel coronavirus.

Learn more about Serology

Customer_Service_300x200.jpg

Our COVID-19 Response

Explore how we're addressing the COVID-19 pandemic and the available products for your laboratory.

View our COVID-19 Portfolio

Abbott’s SARS-CoV-2 tests are for use under an Emergency Use Authorization (EUA) Only:

  • Prescription Use only.
  • These tests have not been FDA cleared or approved.
  • These tests have been authorized by FDA under EUA for use by authorized laboratories.
  • These tests have been authorized only for the detection of IgG and the presence of IgM antibodies against SARS-CoV-2, not for any other viruses or pathogens.
  • These tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

REFERENCES
  1.  Havers FP, Reed C, Lim T, et al. Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020.

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.

Do you wish to continue and exit this website?

Yes No

You are about to enter an Abbott country or region specific website.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.

Do you wish to continue and enter this website?

Yes No

DO YOU WISH TO CONTINUE AND EXIT THE CORE LABORATORY WEBSITE?

Content is not under the control of corelaboratory.abbott.

Yes No